-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection

Reuters·09/30/2026 11:01:51

Please log in to view news